TITLE

Inter-relationships between inflammatory markers in patients with stable COPD with bronchitis: intra-patient and inter-patient variability

AUTHOR(S)
Sapey, E.; Bayley, D.; Ahmad, A.; Newbold, P.; Snell, N.; Stockley, R. A.
PUB. DATE
June 2008
SOURCE
Thorax;Jun2008, Vol. 63 Issue 6, p493
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Measurements of pulmonary biomarkers can be used to monitor airway inflammation in chronic obstructive pulmonary disease )CUPD), but the variability of sampled biomarkers and their inter-relationships are poorly understood. A study was undertaken to examine the intra- and inter-patient variability in spontaneous sputum samples from patients in the stable state and to describe the relationship between biomarkers, cell counts and markers of disease. Methods: Sputum interleukin-1β, tumour necrosis factor α, interleukin 8, myeloperoxidase, leucotriene B4, growth- related oncogene α and differential cell counts were measured in patients with moderate to severe stable COPD (n = 14) on 11 occasions over a 1-month period. Results: There was significant variability in all inflammatory indices (median intra-patient coefficient of variation (CV) 35% )lQR 22-69), median inter-patient CV 102% (IQR 61-1 45)). Variability could be reduced by using a rolling mean of individual patient data points. Sample size calculations were undertaken to determine the number of patients required to detect a 50% reduction in neutrophil count. Using a crossover design of a putative effective treatment, the number needed using one data point per patient was 72, reducing to 23 when a mean of three data points was used. Significant correlations were demonstrated both between the inflammatory biomarkers themselves and between inflammatory biomarkers and markers of disease. Some relationships were not apparent when results from a single sample were used. The reliability of inter-relationships improved as more data points were used for each patient. Conclusions: Clear relationships exist between inflammatory biomarkers in patients with stable COPD. Sequential sampling reduced the variability of individual mediators and the potential number of patients needed to power proof of concept interventional studies.
ACCESSION #
32637215

 

Related Articles

  • Sputum neutrophils as a biomarker in COPD: findings from the ECLIPSE study. Singh, Dave; Edwards, Lisa; Tal-Singer, Ruth; Rennard, Stephen // Respiratory Research;2010, Vol. 11, p77 

    Introduction: The percentage of neutrophils in sputum are increased in COPD patients, and may therefore be a biomarker of airway inflammation. We studied the relationships between sputum neutrophils and FEV1, health status, exacerbation rates, systemic inflammation and emphysema, and long term...

  • The Relation of Serum Myeloperoxidase to Disease Progression and Mortality in Patients with Chronic Obstructive Pulmonary Disease (COPD). Park, Hye Yun; Man, S. F. Paul; Tashkin, Donald; Wise, Robert A.; Connett, John E.; Anthonisen, Nicholas A.; Sin, Don D. // PLoS ONE;Apr2013, Vol. 8 Issue 4, p1 

    Myeloperoxidase is a strong oxidant stored in primary granules of neutrophils with potent antibacterial and proatherogenic properties. Myeloperoxidase has been implicated in the pathogenesis of chronic obstructive pulmonary disease (COPD). However, the relationship of myeloperoxidase to health...

  • Systemic Inflammation in Predicting COPD Exacerbations. Mador, M. Jeffery; Sethi, Sanjay // JAMA: Journal of the American Medical Association;6/12/2013, Vol. 309 Issue 22, p2390 

    An introduction is presented in which the editor discusses various reports within the issue on topics including systemic inflammatory biomarkers, chronic obstructive pulmonary disease (COPD) and Global Initiative for Chronic Obstructive Lung Disease (GOLD) grades.

  • American Journal of Respiratory and Critical Care Medicine.  // Biomedical Market Newsletter;3/21/2012, Vol. 21, p1 

    The article presents information on a study focused on the changes in inflammatory biomarkers that have improved the prediction of the mortality rate in patients with chronic obstructive pulmonary disease (COPD).

  • Plasma YKL-40 and all-cause mortality in patients with chronic obstructive pulmonary disease. Holmgaard, Dennis B.; Mygind, Lone H.; Titlestad, Ingrid L.; Madsen, Hanne; Pedersen, Svend Stenvang; Johansen, Julia S.; Pedersen, Court // BMC Pulmonary Medicine;2013, Vol. 13 Issue 1, p1 

    Background Chronic obstructive pulmonary disease (COPD) is hallmarked by inflammatory processes and a progressive decline of lung function. YKL-40 is a potential biomarker of inflammation and mortality in patients suffering from inflammatory lung disease, but its prognostic value in patients...

  • High Serum YKL-40 Level in Patients with COPD Is Related to Hypoxemia and Disease Severity. Gumus, Aziz; Kayhan, Servet; Cinarka, Halit; Kirbas, Aynur; Bulmus, Necati; Yavuz, Asiye; Sahin, Unal; Ozkaya, Sevket // Tohoku Journal of Experimental Medicine;Feb2013, Vol. 229 Issue 2, p163 

    Chronic obstructive pulmonary disease (COPD) is a major health problem with increasing morbidity and mortality throughout the world. YKL-40 is a chitin-binding glycoprotein consisting of 383 amino acids, with a molecular mass of 40 kDa, and its serum level is elevated in inflammatory diseases....

  • Evaluation of Markers of Inflammation and Oxidative Stress in COPD Patients with or without Cardiovascular Comorbidities. Kaźmierczak, Marcin; Ciebiada, Maciej; Pękala-Wojciechowska, Anna; Pawłowski, Maciej; Nielepkowicz-Goździńska, Agnieszka; Antczak, Adam // Heart, Lung & Circulation;Aug2015, Vol. 24 Issue 8, p817 

    Background Although both chronic obstructive pulmonary disease (COPD) and cardiovascular diseases (CVD) are characterised by chronic, systemic inflammation, their reciprocal interactions are poorly understood. The purpose of this study was to determine the concentrations of both inflammatory and...

  • Depressiveness, symptoms of anxiety and cognitive dysfunctions in patients with asthma and chronic obstructive pulmonary disease (COPD): possible associations with inflammation markers: a pilot study. Bratek, Agnieszka; Zawada, Karolina; Beil-Gawełczyk, Julia; Beil, Sonia; Sozańska, Ewa; Krysta, Krzysztof; Barczyk, Adam; Krupka-Matuszczyk, Irena; Pierzchała, Władysław // Journal of Neural Transmission;Aug2015 Supplement, Vol. 122, p83 

    Psychiatric symptoms of anxiety, depression and cognitive dysfunction often occur in patients suffering from somatic conditions such as asthma and chronic obstructive pulmonary disease (COPD) which constitute a major and growing public health problem. In the present study we therefore aimed at...

  • High Mobility Group Protein B1 (HMGB1) in Asthma: Comparison of Patients with Chronic Obstructive Pulmonary Disease and Healthy Controls. Changchun Hou; Haijin Zhao; Laiyu Liu; Wenjun Li; Xiaoting Zhou; Yanhua Lv; Xiangbo Shen; Zhenyu Liang; Shaoxi Cai; Fei Zou // Molecular Medicine;Jul/Aug2011, Vol. 17 Issue 7/8, p807 

    High mobility group protein B1 (HMGB1) has been implicated as an important mediator in the pathogenesis of asthma and chronic obstructive pulmonary disease (COPD). However, the expression of HMGB1 in plasma and sputum of patients with asthma and COPD across disease severity needs to be defined....

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics